美国13价及新型高价肺炎球菌结合疫苗覆盖血清型所致肺炎球菌疾病负担
该研究基于已发表数据构建Excel模型,估算美国儿童和成人中由PCV13、PCV15和PCV20覆盖血清型所致肺炎球菌疾病的年病例数、死亡数和经济负担。结果显示PCV13血清型所致年病例914199例、死亡4320例;PCV15额外2种血清型所致年病例550475例、死亡1425例;PCV20额外7种血清型所致年病例991220例、死亡3226例。
要点
- PCV13血清型所致年病例914199例、死亡4320例。
- PCV15额外2种血清型所致年病例550475例、死亡1425例。
- PCV20额外7种血清型所致年病例991220例、死亡3226例。
核心结论
- PCV20所含额外血清型对美国儿童和成人肺炎球菌疾病临床和经济负担贡献显著。
- 尽管PCV13儿童国家免疫规划成功且成人PCV13和23价多糖疫苗 uptake 增加,仍需更广泛的PCV血清型覆盖以进一步降低肺炎球菌疾病负担。
研究设计与样本
- 开发基于Excel的模型,使用已发表的年龄组特异性血清型覆盖率、侵袭性肺炎球菌疾病、社区获得性肺炎和急性中耳炎的发病率、病死率及疾病相关成本,估算美国儿童和成人中PCV13、PCV15和PCV20覆盖血清型所致肺炎球菌疾病的年病例数、死亡数和经济负担。
主要发现
- 所有年龄组中,PCV13血清型覆盖的估计年肺炎球菌疾病病例数为914199例,相关死亡为4320例。
- 与PCV13血清型相比,PCV15额外覆盖的2种血清型所致年病例数为550475例,年死亡数为1425例。
- 与PCV13血清型相比,PCV20额外覆盖的7种血清型所致年病例数为991220例,年死亡数为3226例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The addition of pneumococcal conjugate vaccines (PCVs) to the United States (US) national immunization program led to significant reductions in incidence, mortality, and associated sequelae caused by pneumococcal disease (PD) in children and adults through direct and indirect protection. However, there remains clinical and economic burden due to PD caused by serotypes not included in the current 13-valent PCV (PCV13) formulation. To address this unmet need, 15-valent PCV (PCV15) and 20-valent PCV (PCV20), containing additional serotypes to PCV13, were recently approved in the US for adults and are anticipated for pediatrics in the near future. The study objective was to estimate the annual number of cases, deaths, and economic burden of PD due to serotypes included in PCV13, PCV15, and PCV20 for both US pediatric and adult populations. An Excel-based model was developed to calculate clinical and economic outcomes using published age-group specific serotype coverage; incidence of invasive PD, community-acquired pneumonia, and acute otitis media; case fatality rates; and disease-related costs. The results showed that across all age groups, the estimated annual PD cases and associated deaths covered by PCV13 serotypes were 914,199 and 4320, respectively. Compared with PCV13 serotypes, the additional 2 and 7 serotypes covered by PCV15 and PCV20 were attributed with 550,475 and 991,220 annual PD cases, as well as 1425 and 3226 annual deaths, respectively. This clinical burden translates into considerable economic costs ranging from $903 to $1,928 million USD that could be potentially addressed by PCV15 and PCV20. The additional serotypes included in PCV20 contribute substantially to the clinical and economic PD burden in the US pediatric and adult populations. Despite the success of the PCV13 pediatric national immunization program and increased adult uptake of PCV13 and 23-valent polysaccharide vaccine, broader PCV serotype coverage is needed across all ages to further reduce pneumococcal disease burden.
引用
- Huang L, Wasserman M, Grant L, et al. Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States. Vaccine. 2022. PMID: 35753839. doi:10.1016/j.vaccine.2022.06.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。